Head to head
Science 37 vs Curavit
Two decentralized models at different scales.
Science 37
Curavit
Model
Science 37
Full-service DCT providerCuravit
Full-service DCT providerIn one line
Science 37
Decentralized trial operating system with telemedicine investigators and nurses.Curavit
Virtual CRO focused on digital therapeutics and decentralized designs.What they do
Science 37
Provides the components of a decentralized or hybrid trial: patient-facing technology, telemedicine investigators, mobile nursing, and remote coordinators, so enrollment is not limited by proximity to a physical site.Curavit
Operates as a digital-first CRO running virtual and hybrid studies, with particular focus on digital therapeutics and software-based interventions where the product itself is delivered remotely.Pricing
Science 37
Platform plus services, priced per study and per component.Curavit
CRO-style scoped budget with unit costs.Strengths
Science 37
- Removes geography as an enrollment constraint
- Mature DCT technology stack
- Can act as a virtual site alongside your existing network
Curavit
- Positioned specifically for digital therapeutic and software-as-intervention trials
- Lean operating model aimed at smaller sponsors
Watch for
Science 37
- Not every protocol can be decentralized; assessment burden decides
- Adds a regulatory and operational workstream sites are not used to
Curavit
- Ask how many studies it has run in your therapeutic area and who would staff yours
Best for
Science 37
Protocols with remote-friendly assessments and a geographically dispersed population.Curavit
Digital health and DTx sponsors running remote studies.Poor fit
Science 37
Infusion or imaging-heavy protocols requiring frequent on-site procedures.Curavit
Large multinational drug programs with complex safety monitoring.When Science 37 is the right call
Pick Science 37 when you need decentralized infrastructure — telemedicine investigators, mobile nursing, connected devices — operating at multi-country, multi-hundred-patient scale.
When Curavit is the right call
Pick Curavit when the study is a smaller digital-therapeutic or software-as-intervention trial and you want a lean team rather than a platform contract.
How to actually decide
Decide on protocol assessments, not philosophy. List every visit and ask which can genuinely happen at home under your regulatory strategy. If most cannot, neither vendor's decentralized advantage applies and you are buying a conventional trial with extra software. Ask both who staffs your study by name, and how many trials they have run in your therapeutic area.
Do not pick on capability decks. Give both the same brief — your protocol, your countries, your screen failure assumptions — and ask each for the referral-to- randomization ratio they achieved on the three most similar studies they have run. Then price both on cost per randomized patient. The comparison usually resolves itself at that point, and often reveals that neither is the problem: the enrollment assumptions in the protocol were wrong from the start.
Our sister publication Rock Enroll covers that diagnosis in depth for sponsors and CRO teams.